Aspen gets plant in $1.1B GSK deal; Merck cost cuts look at supply chain;

> GlaxoSmithKline ($GSK) has settled on £0.7 billion (about $1.1 billion) for the sale of its Arixtra and Fraxiparine brands to Aspen Pharmaceuticals, a deal that includes a manufacturing facility in France. Release

> Howard Sklamberg, director of the FDA's office of compliance at CEDR, put quality first in his remarks at the RAPS Regulatory Convergence conference this week. Story

> The U.K.'s AMRI ($AMRI) has gotten a 7-year contract to develop and manufacture an active ingredient being evaluated for the country's Defense Science and Technology Laboratory. Release

> The FDA warned doctors and patients not to use the nasal irrigation budesonide solution from The Compounding Shop in St. Petersburg, FL, because it found fungus in a 1000 mL bottle it sampled. Alert

> Park Compounding is voluntarily recalling one lot of the sterile medication Testosterone Cypionate after the FDA raised sterility concerns over results from its testing laboratory. Item

And Finally... Merck's ($MRK) plans to cut $2.5 billion in costs will include efforts to tighten up the company's supply chain costs. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.